UC Davis

UC Davis Previously Published Works

Title

Combination of an oncolytic virus with PD-L1 blockade keeps cancer in check.

Permalink

https://escholarship.org/uc/item/6fx6n419

Journal

Science Translational Medicine, 9(386)

ISSN

1946-6234

Author

Jonas, Brian A

Publication Date

2017-04-19


DOI

10.1126/scitranslmed.aan2781

Copyright Information

This work is made available under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives License, available at https://creativecommons.org/licenses/by-nc-nd/4.0/

Peer reviewed





EDITORS' CHOICE IMMUNOTHERAPY

Combination of an oncolytic virus with PD-L1 blockade keeps cancer in check

Brian A. Jonas

+ See all authors and affiliations

Science Translational Medicine 19 Apr 2017: Vol. 9, Issue 386, eaan2781 DOI: 10.1126/scitransImed.aan2781

Article

Info & Metrics

eLetters

Abstract

An oncolytic vaccinia virus expressing CXCL11 combined with PD-L1 blockade significantly reduces tumor burden and improves survival in murine cancer models.

Cancer immunotherapy has joined surgery, radiation, and chemotherapy as a key pillar of cancer treatment. Checkpoint inhibitors, such as anti–programmed cell death 1 (PD-1) and anti–programmed cell death ligand 1 (PD-L1) antibodies, are now widely used in multiple cancer types. Oncolytic viruses (OV) are immunotherapeutics that can eliminate cancer cells directly through cancer cell death or indirectly through immune activation and alteration of the tumor microenvironment (TME). Efficacy of both checkpoint inhibitors and OV depends on factors such as cancer subtype, PD-1/PD-L1 expression, and the immune milieu. In a new study, Liu *et al.* report that combining an OV promoting PD-L1 expression in both cancer

and TME cells effectively combines with an anti-PD-L1 antibody to overcome these barriers.

Using the Western Reserve strain oncolytic vaccinia virus (v vDD), Liu *et al.* first demonstrated that infection with v vDD led to up-regulation of PD-L1 expression on several murine and human cancer cell lines. Mice bearing murine colon or ovarian cancer cell lines were then treated with control, anti–PD-L1 antibody, a CXCL11-expressing vvDD strain (VV) that enhances T cell infiltration and PD-L1 expression, and the combination of anti–PD-L1 antibody and VV. Combination therapy produced a dramatic antitumor effect and prolonged survival. Significant decreases in myeloid-derived suppressor cells, tumor-associated macrophages, and regulatory T cells were found in the TME of dual-treated tumors. Furthermore, tumor-infiltrating CD4+ and CD8+ effector T cells were increased, with decreased coinhibitory markers and increased activation markers, in the setting of combination therapy. Importantly, long-term surviving mice after dual therapy had significantly impaired tumor growth after tumor reimplantation compared with treatment naïve mice, demonstrating activation of systemic immunity. Depletion experiments showed that CD4+ and CD8+ T cells and IFN-γ were required for combination therapy efficacy.

This study showed that a PD-L1-inducing vaccinia virus strongly combined with PD-L1 blockade to reduce tumor burden and induce long-term survival in murine cancer models. This approach shows the feasibility of using OV to transform anti–PD-L1 resistant tumors into sensitive tumors by enhancing antitumor immunity in the TME and stimulating systemic antitumor immunity. Given the current clinical limitations of OV and checkpoint inhibition approaches, combining OV with PD-L1 blockade represents an exciting new cancer immunotherapy approach with potential broad applicability.

Highlighted Article

Z. Liu, R. Ravindranathan, P. Kalinski, Z. S. Guo, D. L. Bartlett, Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy. *Nat. Commun.* **8**, 14754 (2017).

UC-eLinks UC-eLinks Google Scholar

Copyright © 2017, American Association for the Advancement of Science

View Abstract



Science Translational Medicine Vol 9, Issue 386 19 April 2017

Table of Contents

ARTICLE TOOLS

Email

Save to my folders

Alerts Request Permissions Citation tools Share



SIMILAR ARTICLES IN:

- PubMed
- Google Scholar

Advertisement



Related Jobs

Assistant/Associate/Full Professors

Tucson, Arizona | Salary and start-up funds are attractive and commensurate with qualifications and experience.

Seek outstanding scientist(s) in the general area of cancer immunobiology or cancer immunology.

Employer: University of Arizona

Scientist and Senior Scientist

Mountain View and South San Francisco, California (US) Undisclosed

We are hiring for Research Associates, Scientists, and other leadership roles across biology, protein sciences and related research and development...

Employer: 23andMe

Group Leader Positions at National Institute of Biological Sciences, Beijing

7 Science Park Road, ZGC Life Science Park, Beijing Internationally-competitive salarie+renewable stable funding blocks that cover 5 year periods


Ambitious candidates looking to make high-impact discoveries and exhibiting a high probability of producing creative research are welcomed to apply.

Employer: National Institute of Biological Science, Beijing

MORE JOBS

NAVIGATE THIS ARTICLE

- Article
 - Abstract
 - Highlighted Article
- Info & Metrics
- eLetters



Enter your email address below to receive email announcements from Science. We will also send you a newsletter digest with the latest published articles. See full list Science Translational Medicine TOC Science Table of Contents Science Daily News Science News This Week Science Editor's Choice First Release Notification
About us About journals Leadership Team members Work at AAAS Advertise Advertising kits Custom publishing For subscribers Site license info For members International Chinese Japanose Help Access & subscriptions Reprints & permissions Contact us Accessibility Stay Connected

© 2017 American Association for the Advancement of Science. All rights Reserved. AAAS is a partner of HINARI, AGORA OARE, PatientInform, CHORUS, CLOCKSS, CrossRef and COUNTER. *Science Translational Medicine* ISSN 1946-6242.

Terms of Service Privacy Policy Contact Us